Canada markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.10000.0000 (0.00%)
At close: 03:54PM EDT
Full screen
Previous Close0.1000
Open0.1000
Bid0.0950 x N/A
Ask0.1000 x N/A
Day's Range0.0850 - 0.1000
52 Week Range0.0050 - 0.1350
Volume60,000
Avg. Volume29,384
Market Cap8.928M
Beta (5Y Monthly)0.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement

    All dollar amounts reflected in Canadian dollars unless otherwise stated.VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024, July 19, 2024, and July 22, 2024, the Company has closed its previously announced over-subscribed non-bro

  • GlobeNewswire

    Rakovina Therapeutics Provides Update on Previously Announced Private Placement

    All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024 and July 19, 2024, the Company has received subscriptions for an aggregate of $2,000,000 worth of units o

  • GlobeNewswire

    Rakovina Therapeutics Announces Second Upsizing of Private Placement

    All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press releases dated May 23, 2024 and June 20, 2024, that to accommodate additional indications of interest it will upsize the previously announce